DK2691529T3 - AAV2-partikel omfattende et AAV2-kapsidprotein og en vektor omfattende en nukleinsyre, der koder for en tripeptidylpeptidase 1 (TPP1) til anvendelse til behandling af sen infantil ceroid lipofuscinose (LINCL) hos et ikke-gnaver pattedyr ved intraventrikulær injektion eller ICV-indgivelse - Google Patents
AAV2-partikel omfattende et AAV2-kapsidprotein og en vektor omfattende en nukleinsyre, der koder for en tripeptidylpeptidase 1 (TPP1) til anvendelse til behandling af sen infantil ceroid lipofuscinose (LINCL) hos et ikke-gnaver pattedyr ved intraventrikulær injektion eller ICV-indgivelse Download PDFInfo
- Publication number
- DK2691529T3 DK2691529T3 DK12763234.7T DK12763234T DK2691529T3 DK 2691529 T3 DK2691529 T3 DK 2691529T3 DK 12763234 T DK12763234 T DK 12763234T DK 2691529 T3 DK2691529 T3 DK 2691529T3
- Authority
- DK
- Denmark
- Prior art keywords
- aav2
- lincl
- tpp1
- vector
- nucleic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161470460P | 2011-03-31 | 2011-03-31 | |
| PCT/US2012/031896 WO2012135857A1 (en) | 2011-03-31 | 2012-04-02 | Methods and compositions for treating brain diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2691529T3 true DK2691529T3 (da) | 2019-09-23 |
Family
ID=46931978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12763234.7T DK2691529T3 (da) | 2011-03-31 | 2012-04-02 | AAV2-partikel omfattende et AAV2-kapsidprotein og en vektor omfattende en nukleinsyre, der koder for en tripeptidylpeptidase 1 (TPP1) til anvendelse til behandling af sen infantil ceroid lipofuscinose (LINCL) hos et ikke-gnaver pattedyr ved intraventrikulær injektion eller ICV-indgivelse |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9849195B2 (da) |
| EP (2) | EP2691529B1 (da) |
| CA (1) | CA2832151C (da) |
| DK (1) | DK2691529T3 (da) |
| ES (1) | ES2745470T3 (da) |
| PT (1) | PT2691529T (da) |
| WO (1) | WO2012135857A1 (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105377039A (zh) | 2013-05-15 | 2016-03-02 | 明尼苏达大学董事会 | 腺相关病毒介导的基因向中枢神经系统转移 |
| MX2016001026A (es) * | 2013-07-26 | 2016-08-03 | Univ Iowa Res Found | Metodos y composiciones para tratar enfermedades del cerebro. |
| US20170336395A1 (en) * | 2013-11-20 | 2017-11-23 | University Of Iowa Research Foundation | Methods and compositions for treating amyloid deposits |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| US20180289839A1 (en) * | 2015-05-15 | 2018-10-11 | Regents Of The University Of Minnesota | Intranasal therapeutic delivery of adeno-associated virus to central nervous system |
| AU2016341428B2 (en) * | 2015-10-23 | 2021-12-02 | University Of Iowa Research Foundation | Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection |
| US10927155B2 (en) | 2015-11-19 | 2021-02-23 | George Mason Research Foundation, Inc. | Dual inhibitory action peptidomimetic inhibitor for IL-33 and IL-1beta |
| EP3452104A1 (en) | 2016-04-15 | 2019-03-13 | The Trustees of The University of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
| AU2017355502B2 (en) * | 2016-11-04 | 2023-08-31 | The Children's Hospital Of Philadelphia | Gene transfer compositions, methods and uses for treating neurodegenerative diseases |
| MX2019013528A (es) * | 2017-05-12 | 2020-07-14 | The Children´S Hospital Of Philadelphia | Variantes de sulfamidasa (sgsh) y vectores, composiciones, metodos y usos para tratar la mucopolisacaridosis tipo iiia (mps iiia). |
| AU2018281280A1 (en) | 2017-06-07 | 2020-01-16 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| EP3684938A1 (en) | 2017-09-22 | 2020-07-29 | The Trustees of the University of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
| EP3880235A4 (en) * | 2018-11-14 | 2022-08-10 | REGENXBIO Inc. | GENE THERAPY OF NEURAL ZEROID LIPOFUSCINOSES |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3802595A (en) | 1994-11-08 | 1996-05-31 | Novo Nordisk A/S | Tripeptidyl aminopeptidase |
| US20020037867A1 (en) | 1999-02-26 | 2002-03-28 | James M. Wilson | Method for recombinant adeno-associated virus-directed gene therapy |
| US6302685B1 (en) | 1997-09-16 | 2001-10-16 | University Of Medicine And Dentistry Of New Jersey | Human lysosomal protein and methods of its use |
| US6468524B1 (en) | 2000-03-22 | 2002-10-22 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | AAV4 vector and uses thereof |
| US6855314B1 (en) | 2000-03-22 | 2005-02-15 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector for transducing brain cells and lung cells |
| CA2438750A1 (en) | 2001-02-20 | 2002-08-29 | Uab Research Foundation | Aminoglycoside treatment for lysosomal storage diseases |
| AU2004281764B2 (en) * | 2003-10-14 | 2011-04-07 | Neurologix Research, Inc. | Methods and compositions for the treatment of neurological disease |
| WO2008049058A2 (en) | 2006-10-18 | 2008-04-24 | Cornell Research Foundation, Inc. | Cln2 treatment of alzheimer's disease |
| CA2684946C (en) | 2007-05-16 | 2015-03-31 | The Brigham And Women's Hospital, Inc. | Treatment of synucleinopathies |
| PT2158322T (pt) * | 2007-06-06 | 2017-08-09 | Genzyme Corp | Terapia genética para doenças do armazenamento lisossomal |
| DK2176283T3 (da) | 2007-07-14 | 2017-02-13 | Univ Iowa Res Found | Fremgangsmåder og sammensætninger til behandling af hjernesygdomme |
| US9750712B2 (en) | 2012-12-07 | 2017-09-05 | Rush University Medical Center | Composition and method for treating neuronal ceroid lipofuscinosis |
| GB201308917D0 (en) | 2013-05-17 | 2013-07-03 | Renishaw Plc | Delivery |
-
2012
- 2012-04-02 EP EP12763234.7A patent/EP2691529B1/en active Active
- 2012-04-02 US US14/008,994 patent/US9849195B2/en active Active
- 2012-04-02 PT PT12763234T patent/PT2691529T/pt unknown
- 2012-04-02 WO PCT/US2012/031896 patent/WO2012135857A1/en active Application Filing
- 2012-04-02 CA CA2832151A patent/CA2832151C/en active Active
- 2012-04-02 DK DK12763234.7T patent/DK2691529T3/da active
- 2012-04-02 ES ES12763234T patent/ES2745470T3/es active Active
- 2012-04-02 EP EP19170680.3A patent/EP3546584B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012135857A9 (en) | 2012-10-26 |
| WO2012135857A1 (en) | 2012-10-04 |
| US20140088179A1 (en) | 2014-03-27 |
| PT2691529T (pt) | 2019-09-27 |
| ES2745470T3 (es) | 2020-03-02 |
| EP2691529A4 (en) | 2014-12-10 |
| US9849195B2 (en) | 2017-12-26 |
| CA2832151C (en) | 2021-06-15 |
| EP3546584A1 (en) | 2019-10-02 |
| EP3546584B1 (en) | 2024-02-14 |
| CA2832151A1 (en) | 2012-10-04 |
| EP2691529A1 (en) | 2014-02-05 |
| EP2691529B1 (en) | 2019-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2691529T3 (da) | AAV2-partikel omfattende et AAV2-kapsidprotein og en vektor omfattende en nukleinsyre, der koder for en tripeptidylpeptidase 1 (TPP1) til anvendelse til behandling af sen infantil ceroid lipofuscinose (LINCL) hos et ikke-gnaver pattedyr ved intraventrikulær injektion eller ICV-indgivelse | |
| HK1207758A1 (en) | Abstracted and randomized one-time passwords for transactional authentication | |
| IL244154A0 (en) | Botulinum neurotoxin for use in the treatment of depression | |
| DK2839014T3 (da) | Sammensætning og fremgangsmåder til højeffektiv genoverførsel ved anvendelse af aav-capsid-varianter | |
| BR112015002541A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente. | |
| LU91805B1 (fr) | Compositions inhibitrices de virus pour une utilisation therapeutique in vivo | |
| DK3130347T3 (da) | PH20-polypeptidvarianter, formuleringer og anvendelser deraf | |
| EP2694660A4 (en) | EFFICIENT IN VIVO PROTEIN EXPRESSION USING MODIFIED RNA (MOD RNA) | |
| DK2320911T3 (da) | Vasokonstriktionspræparater og fremgangsmåder til anvendelse deraf | |
| WO2013177398A3 (en) | Non-natural consensus albumin binding domains | |
| DK3115372T3 (da) | Målrettede terapeutiske lysosomale enzymfusionsproteiner og anvendelser deraf | |
| DK2273975T3 (da) | Farmaceutiske opløsninger, fremgangsmåde til fremstilling og terapeutiske anvendelser | |
| DK4066855T3 (da) | Pegylerede liposomer til forsyning af RNA, der koder for immunogen | |
| BR112014022788A2 (pt) | peptídeo, polipeptídeos, ácido nucleico, composição farmacêutica, conjugado e método in vitro | |
| BRPI0915142A2 (pt) | polipeptídeos, ácido nucleico e usos dos mesmos | |
| DK3301107T3 (da) | Nye peptider der bindes til typer af mhc klasse ii og deres anvendelse ved diagnosticering og behandling | |
| GB0800927D0 (en) | Botulinum neurotoxin vaccine | |
| BRPI1005433A2 (pt) | preparações farmacêuticas transdérmicas | |
| DK2488649T3 (da) | Rekombinant modificeret vaccinia ankara (mva)-vaccinia-virus indeholdende restrukturerede insertionssteder | |
| ZA201306009B (en) | Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same | |
| DK2470520T3 (da) | Chromonderivater, fremgangsmåde til fremstilling af disse og deres terapeutiske anvendelser | |
| DK2328417T3 (da) | FORBINDELSER, PRÆPARATER OG FREMGANGSMÅDER TIL BEHANDLING AF beta-AMYLOIDSYGDOMME OG SYNUKLEINOPATIER | |
| DK2650049T3 (da) | Hydrogenbehandlingskatalysator og fremgangsmåde til fremstilling af denne | |
| BR112014003556A2 (pt) | método de tratamento de vírus, e, composição farmacêutica | |
| DK2859092T3 (da) | Terapeutisk vaccine til behandling af diabetes type-1 hos børn, anvendelse af cellesorter og fremgangsmåde til at multiplicere treg-celler til fremstilling af terapeutisk vaccine til behandling af diabetes type-1 |